secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016950
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed approves new cash bonus plan and equity policies for 2025
--------------------------------------------------------------------------

- CEO Hochman and President Sherman eligible for 80% base salary cash bonus; CFO Taylor eligible for 50%.
- 2025 goals include BACKBEAT enrollment, Virtue Sirolimus program milestones, pipeline/partnerships, financial objectives.
- Stretch goals can boost bonus up to 60%; CFO bonus further adjustable up to 45% or zero on individual performance.
- VP+ officers may elect equity as 100% options, 100% RSUs, or 50/50; RSUs vest over 3 years starting at 24 months.
- Section 16 officers' RSU tax liabilities satisfied by share withholding, not market sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925016950/0001104659-25-016950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465925016950/tm257515d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer